Development of hypotension in patients newly diagnosed with heart failure in UK general practice: retrospective cohort and nested case-control analyses.
Adolescent
Adult
Aged
Aged, 80 and over
Cardiovascular Agents
/ adverse effects
Case-Control Studies
Comorbidity
Databases, Factual
Female
General Practice
/ statistics & numerical data
Heart Failure
/ drug therapy
Humans
Hypotension
/ chemically induced
Incidence
Male
Middle Aged
Retrospective Studies
Risk Factors
United Kingdom
/ epidemiology
Young Adult
blood pressure
heart failure
hypotension
incidence
primary care
risk factors
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
11 07 2019
11 07 2019
Historique:
entrez:
14
7
2019
pubmed:
14
7
2019
medline:
9
7
2020
Statut:
epublish
Résumé
Hypotension is of particular relevance for patients with heart failure (HF), since almost all HF drugs cause lowering of blood pressure (BP) and it is associated with a poor prognosis. We aimed to investigate hypotension incidence and risk factors in patients with incident HF in the UK. Retrospective cohort study including nested case-control analyses. The Health Improvement Network UK primary care database. 18 677 adult patients with incident HF during 2000-2005 were followed and cases of hypotension (systolic BP ≤90 mm Hg) were identified. Controls were age-matched, sex-matched and date-matched to cases (1:2). We estimated hypotension incidence in the full study population and relevant subgroups (eg, sex and age). Potential risk factors for hypotension overall and for multiple versus single hypotensive episodes were evaluated using conditional logistic regression and unconditional regression models, respectively. During a mean follow-up of 3.31 years, 2565 patients (13.7%) developed hypotension. The incidence of hypotension was 3.17 cases per 100 patient years (95% confidence interval (CI): 3.05-3.30), and was markedly increased in women aged 18-39 years (n=32; 17.72 cases per 100 patient-years; 95% CI: 9.69-29.73). Hypotension risk factors included high healthcare utilisation (proxy measure for HF severity and general comorbidity; eg, ≥10 primary care physician visits versus none, odds ratio (OR): 2.29; 95% CI: 1.34-3.90), previous hypotensive episodes (OR: 2.32; 95% CI: 1.84-2.92), renal failure and use of aldosterone antagonists, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Risk factors identified for hypotension generally overlapped with those for multiple versus single hypotensive episodes. Hypotension occurs frequently in patients with incident HF. Our findings may help identify patients most likely to benefit from close BP monitoring. The increased incidence of hypotension in young women with HF requires investigation.
Identifiants
pubmed: 31300503
pii: bmjopen-2018-028750
doi: 10.1136/bmjopen-2018-028750
pmc: PMC6629451
doi:
Substances chimiques
Cardiovascular Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e028750Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: MM-P and LAGR work for CEIFE, which has received a research grant from Bayer Pharma AG, Germany. LAGR has also served as an advisory board member for Bayer Pharma AG, Germany. AM is a salaried, full-time employee of Bayer Basel, Switzerland. MM is a salaried, full-time employee of Bayer US LLC., USA.
Références
J Am Coll Cardiol. 2008 Dec 9;52(24):2000-7
pubmed: 19055992
J Am Coll Cardiol. 2004 Apr 21;43(8):1423-9
pubmed: 15093878
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Ther Adv Drug Saf. 2015 Aug;6(4):166-76
pubmed: 26301070
Heart Fail Rev. 2013 Mar;18(2):107-22
pubmed: 22581217
Eur Heart J. 2001 Sep;22(17):1527-60
pubmed: 11492984
Congest Heart Fail. 2013 May-Jun;19(3):107-15
pubmed: 23241032
J Am Coll Cardiol. 2006 Oct 17;48(8):1527-37
pubmed: 17045884
Proc AMIA Annu Fall Symp. 1996;:75-9
pubmed: 8947631
Eur J Heart Fail. 2005 Aug;7(5):710-21
pubmed: 16087129
Nat Rev Endocrinol. 2014 Jun;10(6):364-76
pubmed: 24732974
Eur J Heart Fail. 2014 Jan;16(1):86-94
pubmed: 23901055
Eur Heart J. 2015 Jul 1;36(25):1609-17
pubmed: 25852216
J Hum Hypertens. 2000 Apr;14(4):243-7
pubmed: 10805049
J R Soc Med. 1982 Aug;75(8):577-80
pubmed: 7050378
Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):393-401
pubmed: 17066486
Yale J Biol Med. 2016 Mar 24;89(1):59-71
pubmed: 27505017
Circ Heart Fail. 2012 Nov;5(6):820-1
pubmed: 23170022
Inform Prim Care. 2011;19(4):251-5
pubmed: 22828580
Can J Cardiol. 2018 May;34(5):575-584
pubmed: 29459239
N Engl J Med. 1991 Aug 1;325(5):293-302
pubmed: 2057034
N Engl J Med. 1987 Jun 4;316(23):1429-35
pubmed: 2883575
J Am Coll Cardiol. 2002 Jun 5;39(11):1780-6
pubmed: 12039491
Circ Heart Fail. 2015 Jul;8(4):826-31
pubmed: 26199309
J Am Med Dir Assoc. 2016 Dec 1;17(12):1076-1088
pubmed: 27523406
Ter Arkh. 2014;86(4):8-12
pubmed: 24864461
Inform Prim Care. 2004;12(3):171-7
pubmed: 15606990
J Card Fail. 2009 Dec;15(10):906-11
pubmed: 19944368
JAMA. 2006 Nov 8;296(18):2217-26
pubmed: 17090768
Cardiorenal Med. 2012 Dec;2(4):281-297
pubmed: 23381594
J Am Coll Cardiol. 2003 Jun 4;41(11):1933-9
pubmed: 12798560
J Neurochem. 2016 Oct;139 Suppl 1:318-324
pubmed: 27401947
Am Heart J. 2011 Mar;161(3):567-73
pubmed: 21392613
J Am Coll Cardiol. 2003 Jan 15;41(2):211-4
pubmed: 12535810